(5) Although pCR is a validated surrogate endpoint for long-term survival in HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy (2), direct assessment of event-free survival (EFS) and overall survival (OS) will provide more definitive evidence. This evidence concerns the gene ERBB2 and breast carcinoma.